Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
86 hedge funds and large institutions have $433M invested in Forte Biosciences in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 12 closing their positions.
158% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 12
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
26% more funds holding
Funds holding: 68 → 86 (+18)
24% more capital invested
Capital invested by funds: $350M → $433M (+$82.5M)
8.5% less ownership
Funds ownership: 107.94% → 99.43% (-8.5%)
82% less call options, than puts
Call options by funds: $315K | Put options by funds: $1.8M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.4M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$21.8M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$12.4M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$9.03M |
| 5 |
O
OrbiMed
New York
|
+$9.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.93M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.83M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.32M |
FBRX Hedge Fund Activity: Q2 2026 in Review
86 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q2 2026, worth a combined $433M — up 24% from $350M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new FBRX positions and 12 closed out — a net gain of 19 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $27.4M. The largest seller was Morgan Stanley, cutting an estimated $10.8M.
- 86 institutional investors held Forte Biosciences (FBRX) as of Q2 2026, up from 68 in Q1 2026.
- Funds reported $433M of Forte Biosciences stock for Q2 2026, up 24% quarter-over-quarter.
- 31 funds opened new Forte Biosciences positions in Q2 2026 and 12 closed out, a net change of +19 holders.
- The largest Forte Biosciences buyer in Q2 2026 was BlackRock, an estimated $27.4M added.
- The largest Forte Biosciences seller in Q2 2026 was Morgan Stanley, an estimated $10.8M sold.
Based on aggregated 13F filings for Q2 2026.